Search Results for: FORMULATION DEVELOPMENT TECHNOLOGY A Novel
Articles
BioNTech Announces Strategic Transaction to Acquire CureVac June 13, 2025
BioNTech SE and CureVac N.V. recently announced they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to...Elicio Therapeutics Secures $10 Million in Financing June 4, 2025
Elicio Therapeutics, Inc. recently announced it has entered a $10-million senior secured promissory note with existing investor, GKCC, LLC. The...EXECUTIVE INTERVIEW - Adare Pharma Solutions: Fast, Flexible, and Focused: The Secrets of a Successful CDMO Partnership June 3, 2025
Steven Facer, Senior Vice President of Sales and Marketing at Adare Pharma Solutions, shares practical insights on what makes CDMO partnerships work and what can cause them to fall short.
Hovione & Firstgene Announce Strategic Collaboration to Advance Virus-Like Particle Platform for Liver Cancer May 14, 2025
Hovione and Firstgene Life Sciences recently announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for...Alzamend Neuro Initiates First Phase 2 Trial of AL001 “Lithium in Brain” Study May 13, 2025
Alzamend Neuro, Inc. recently today announced the initiation of the first of five Phase 2 clinical studies of AL001, with...SPECIAL FEATURE - PFS & Parenteral Delivery: Innovation Is Focused on Patient-Centric, Smart & Sustainable Solutions May 7, 2025
Contributor Cindy H. Dubin speaks with several innovating companies to discuss trends in PFS as well as advancements in autoinjectors and innovations in parenteral delivery.
EXECUTIVE INTERVIEW - MediWound Ltd.: Developing a New Class of Biologic Enzymatic Therapeutic Products to Debride Wounds May 6, 2025
Ofer Gonen, Chief Executive Officer of MediWound, discusses the company’s innovative approach to debridement.
Inmagene Reports Topline Results From Phase 2a Study of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life in Patients With Alopecia Areata April 24, 2025
Inmagene Biopharmaceuticals recently reports topline results from the Phase 2a trial of IMG-007 in patients with severe alopecia areata (AA)....Ligand Subsidiary Pelthos Therapeutics to Combine With Channel Therapeutics April 17, 2025
Ligand Pharmaceuticals Incorporated and Channel Therapeutics Corporation recently announced the signing of a definitive merger agreement to combine Ligand’s wholly...Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine March 18, 2025
Curevo Vaccine recently announced the closing of a $110-million Series B round to advance development of amezosvatein, its vaccine for...Polyrizon Signs Non–Binding LOI to Expand its Innovative Intranasal Drug Delivery Platform for Psychedelic-Based Treatments March 14, 2025
Polyrizon Ltd. recently announced it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived...SPECIAL FEATURE - Analytical Testing – Diverse Demands & Therapies Require Diverse Analyses February 11, 2025
Contributor Cindy H. Dubin highlights how analytical testing has evolved to address diverse pharmaceutical therapeutics in research and development.
MICRONEEDLE MANUFACTURING - The Value of a Manufacturing-Oriented Microneedle Mindset February 10, 2025
Andrew Riso says despite the significant buzz surrounding microneedle technology, a considerable gap remains between innovations and market-ready products. While early stage development and preclinical studies have shown promising results, the challenge of translating these advancements into scalable, commercially viable products persists.
NEW PRODUCT INTRODUCTION - Addressing the Pitfalls of Progressing From Pilot to Product Through Effective New Product Introduction February 10, 2025
Uwe Hanenberg, PhD, Wolfram Bühler, and Radoslaw Kaczanowski, PhD, explore the risks and challenges pharmaceutical companies face when undertaking NPI to ensure new products successfully reach the market and patients and examine the strategies CDMOs are adopting to ensure the smooth delivery of these projects from discovery to commercialization.
Sanara MedTech Inc. Announces Exclusive License & Distribution Agreement With & Minority Investment in Biomimetic Innovations Ltd January 22, 2025
Sanara MedTech Inc. recently announced the execution of an exclusive license and distribution agreement with Biomimetic Innovations Ltd. In tandem,...Inmagene Reports Positive Topline Results of a Nondepleting Anti-OX40 Monoclonal Antibody With an Extended Half-Life for the Treatment of Atopic Dermatitis January 9, 2025
Inmagene Biopharmaceuticals reports additional positive topline results from the Phase 2a trial of IMG-007 in patients with moderate-to-severe AD, along...Silo Pharma Awarded Patent for Groundbreaking PTSD Treatment January 8, 2025
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) issued a Notice of Allowance for patent application...Ikena Oncology & Inmagene Biopharmaceuticals Announce Agreement for Merger & Private Placement December 23, 2024
Ikena Oncology, Inc. and Inmagene Biopharmaceuticals recently announced they have entered into a definitive merger agreement. In connection with the...ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative December 19, 2024
ABVC BioPharma, Inc. recently announced in response to the discontinuation of Prozac due to increasing concerns around side effects, ABVC...SCYNEXIS Initiates Dosing in Phase 1 Trial of a Second-Generation Fungerp Candidate for Invasive Fungal Infections December 18, 2024
SCYNEXIS, Inc. recently announced it has completed the dosing of the first cohort of subjects in its Phase 1 trial...Company Profiles
Lyophilization Technology, Inc.
Lyophilization Technology, Inc. 30 Indian Drive Ivyland, PA 18974-1431 T: (215) 396-8373 F: (215) 396-8375 E: inquiry@lyo-t.com W: www.lyotechnology.com WHO...
